Press release
Janus Kinase (JAK) Inhibitors Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma
The Janus Kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Janus Kinase (JAK) Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitors Market.
Some of the key takeaways from the Janus Kinase (JAK) Inhibitors Pipeline Report: https://www.delveinsight.com/sample-request/mayus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Janus Kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years.
• Janus Kinase (JAK) Inhibitors companies working in the treatment market are Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others, are developing therapies for the Janus Kinase (JAK) Inhibitors treatment
• Emerging Janus Kinase (JAK) Inhibitors therapies in the different phases of clinical trials are- Research programme: JAK2 inhibitors Ajax Therapeutics, SDC 1802, INCB-160058, ATI-2138, AZD 4604, CPL409116, Zasocitinib, Povorcitinib, Upadacitinib, Baricitinib, and others are expected to have a significant impact on the Janus Kinase (JAK) Inhibitors market in the coming years.
• In July 2024, Sun Pharmaceutical Industries Limited (Sun Pharma) and its subsidiaries have announced that the U.S. Food and Drug Administration (FDA) has granted approval for LEQSELVITM (deuruxolitinib) 8 mg tablets. This medication is indicated for the treatment of adults with severe alopecia areata.
• In March 2024, Incyte released findings from a Phase II trial assessing the effectiveness and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adults with prurigo nodularis (PN). These results were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting held from March 8-12, 2024, in San Diego.
Janus Kinase (JAK) Inhibitors Overview
Janus kinase (JAK) inhibitors are a class of medications that target the Janus kinase enzymes, specifically JAK1, JAK2, JAK3, and TYK2. These enzymes are involved in signaling pathways that regulate the immune system and inflammatory processes. By inhibiting JAK enzymes, JAK inhibitors can modulate immune responses and reduce inflammation.
Get a Free Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mayus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Janus Kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:
• Research programme: JAK2 inhibitors Ajax Therapeutics
• SDC 1802: Sareum
• INCB-160058: Incyte Corporation
• ATI-2138: Aclaris Therapeutics
• AZD 4604: AstraZeneca
• CPL409116: Celon Pharma
• Zasocitinib: Takeda
• Povorcitinib: Incyte Corporation
• Upadacitinib: AbbVie
• Baricitinib: Eli Lilly and Company
Janus Kinase (JAK) Inhibitors Route of Administration
Janus Kinase (JAK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Janus Kinase (JAK) Inhibitors Molecule Type
Janus Kinase (JAK) Inhibitors Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Janus Kinase (JAK) Inhibitors Pipeline Therapeutics Assessment
• Janus Kinase (JAK) Inhibitors Assessment by Product Type
• Janus Kinase (JAK) Inhibitors By Stage and Product Type
• Janus Kinase (JAK) Inhibitors Assessment by Route of Administration
• Janus Kinase (JAK) Inhibitors By Stage and Route of Administration
• Janus Kinase (JAK) Inhibitors Assessment by Molecule Type
• Janus Kinase (JAK) Inhibitors by Stage and Molecule Type
DelveInsight's Janus Kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Janus Kinase (JAK) Inhibitors product details are provided in the report. Download the Janus Kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus Kinase (JAK) Inhibitors therapies
https://www.delveinsight.com/sample-request/mayus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Janus Kinase (JAK) Inhibitors Therapeutics Market include:
Key companies developing therapies for Janus Kinase (JAK) Inhibitors are - Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, and others.
Janus Kinase (JAK) Inhibitors Pipeline Analysis:
The Janus Kinase (JAK) Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Janus Kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors Treatment.
• Janus Kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Janus Kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus Kinase (JAK) Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors drugs and therapies
https://www.delveinsight.com/sample-request/mayus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Janus Kinase (JAK) Inhibitors Pipeline Market Drivers
• JAK inhibitors offer therapeutic benefits by modulating the immune system and reducing inflammation in conditions like rheumatoid arthritis and psoriasis. This trend is fueling the growth of the JAK inhibitor market, addressing unmet medical needs in rheumatology and dermatology.
Janus Kinase (JAK) Inhibitors Pipeline Market Barriers
• Janus kinase (JAK) Inhibitors pricing is still highly uncontrolled and determined on a case-by-case basis in many nations, frequently focusing on a single upfront payment.
Scope of Janus Kinase (JAK) Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key Janus Kinase (JAK) Inhibitors Companies: Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others
• Key Janus Kinase (JAK) Inhibitors Therapies: Research programme: JAK2 inhibitors Ajax Therapeutics, SDC 1802, INCB-160058, ATI-2138, AZD 4604, CPL409116, Zasocitinib, Povorcitinib, Upadacitinib, Baricitinib, and others
• Janus Kinase (JAK) Inhibitors Therapeutic Assessment: Janus Kinase (JAK) Inhibitors current marketed and Janus Kinase (JAK) Inhibitors emerging therapies
• Janus Kinase (JAK) Inhibitors Market Dynamics: Janus Kinase (JAK) Inhibitors market drivers and Janus Kinase (JAK) Inhibitors market barriers
Request for Sample PDF Report for Janus Kinase (JAK) Inhibitors Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/mayus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Janus Kinase (JAK) Inhibitors Report Introduction
2. Janus Kinase (JAK) Inhibitors Executive Summary
3. Janus Kinase (JAK) Inhibitors Overview
4. Janus Kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment
5. Janus Kinase (JAK) Inhibitors Pipeline Therapeutics
6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase II/III)
7. Janus Kinase (JAK) Inhibitors Mid Stage Products (Phase II)
8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase I)
9. Janus Kinase (JAK) Inhibitors Preclinical Stage Products
10. Janus Kinase (JAK) Inhibitors Therapeutics Assessment
11. Janus Kinase (JAK) Inhibitors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Janus Kinase (JAK) Inhibitors Key Companies
14. Janus Kinase (JAK) Inhibitors Key Products
15. Janus Kinase (JAK) Inhibitors Unmet Needs
16 . Janus Kinase (JAK) Inhibitors Market Drivers and Barriers
17. Janus Kinase (JAK) Inhibitors Future Perspectives and Conclusion
18. Janus Kinase (JAK) Inhibitors Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports Offered By DelveInsight:
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Janus Kinase (JAK) Inhibitors Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma here
News-ID: 3888803 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for JAK
Key Trends Influencing the Growth of the Janus Kinase (JAK) Inhibitors Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Janus Kinase (JAK) Inhibitors Market Through 2025?
The market size of Janus Kinase (JAK) inhibitors has experienced a quick growth over the recent years. The market, which stood at $20.19 billion in 2024, is projected to see a rise to $23.56 billion…
Vitiligo Treatment Innovation Accelerates with JAK Inhibitors and Novel Immunoth …
Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving the Vitiligo treatment landscape. Let's explore how this will impact the Vitiligo treatment landscape.
DelveInsight's "Vitiligo Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights on the vitiligo pipeline, showcasing a dynamic landscape of emerging therapies and a promising outlook for patients suffering from this challenging autoimmune skin…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth?
The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune…
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase…
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Janus kinase Inhibitors Report
• DelveInsight's Janus kinase Inhibitors report depicts a robust space…
